Aytu Biopharma (AYTU) Net Equity Issued and Repurchased (2010 - 2023)

Aytu Biopharma (AYTU) has reported Net Equity Issued and Repurchased for 10 consecutive years, with $2.6 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Net Equity Issued and Repurchased rose 354.77% year-over-year to $2.6 million in Q2 2023; TTM through Mar 2024 was $3.0 million, a 76.64% decrease from a year earlier, with the FY2023 full-year figure at $15.6 million, up 33.19% from the prior year.
• Net Equity Issued and Repurchased was $2.6 million for Q2 2023 at Aytu Biopharma, up from $1.4 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $12.8 million in Q2 2021 and troughed at -$1.0 million in Q2 2022.
• A 3-year average of $4.1 million and a median of $2.6 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 107.86% in 2022 and soared 354.77% in 2023, its largest moves.
• Over 3 years, Net Equity Issued and Repurchased stood at $4.5 million in 2021, then slumped by 122.27% to -$1.0 million in 2022, then jumped by 354.77% to $2.6 million in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $2.6 million (Q2 2023), $1.4 million (Q1 2023), and -$1.0 million (Q2 2022), per Business Quant data.